BioCentury
ARTICLE | Analyst Picks & Changes

Analyst picks & changes

November 8, 1993 8:00 AM UTC

Repligen Corp.

Mark Simon of Robertson, Stephens initiated coverage of Repligen Corp. with a "buy" up to $12. The stock is just $1.50 above its low, with a market cap of $83 million, because RGEN is viewed as just another early biotech company trying to develop a treatment for AIDS, he said. But in fact, RGEN has substantially added to its product pipeline. ...